{
  "docId": "019de077-4649-72e2-aa45-017392de211d",
  "docSlug": "8a7a8508ae9537047e1aabcda9819db4",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 27 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 27,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4649-72e2-aa45-017392de211d/24",
  "deckHref": "/decks/019de077-4649-72e2-aa45-017392de211d",
  "deckJsonHref": "/decks/019de077-4649-72e2-aa45-017392de211d.json",
  "deckAnchorHref": "/decks/019de077-4649-72e2-aa45-017392de211d#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.86,
        "x": 0.068,
        "y": 0.238
      },
      "kind": "diagram",
      "text": "2024 and 2025 timeline arrow",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7c76a22-ba9e-49bd-856b-23894ba7547c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.58,
        "y": 0.39
      },
      "kind": "list",
      "text": "Meeting with EMA on ALS phase 3 (Q2); ALS phase 3 FPI (H1); Ongoing AD (RoAD) trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "044a4481-695b-4e62-871c-a64f4668d723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.12,
        "y": 0.39
      },
      "kind": "list",
      "text": "Neurofilament and iron plasma results; Safety, functional efficacy and survival 6- and 12- month data; PARADIGM 18-month data; Additional PARADIGM biomarker results; Meeting with the FDA on ALS phase 3 (Q4); End of PARADIGM phase 2b trial (Q4)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f819fd2-40c0-4de3-8683-c41851ef70a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.077,
        "y": 0.085
      },
      "kind": "title",
      "text": "Upcoming Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81d5d9b3-e927-43db-8495-2207ffcdcc05",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "89d3e3a2-b2d2-4457-ac12-84184ca1556e",
      "evidence": "Chronological presentation of future company milestones.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}